* pregnancy, nursing mothers, and women of childbearing potential who are unable to use adequate contraception. * known hypersensitivity or other clear contraindication to the use of colchicine. * history of end-stage renal disease (egfr \<30 ml / min / 1.73 m2). * medical history of cirrhosis (child-pugh c), liver failure, chronic active hepatitis, or severe liver disease defined by alanine aminotransferase (alt) or aspartate aminotransferase (ast)\> 5 times the upper limit of normal. * history of pre-existing neuromuscular disease. * previous severe hematologic disease or bleeding disorders. * inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea, or malabsorptive syndrome. * colchicine treatment for other indications. * treatment with immunosuppressive/immunomodulatory agents, including glucocorticoids, antivirals, antimalarials, and il 6 antagonists for 30 days prior to enrollment. * use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion. * any medical condition or disease that, in the opinion of the investigator, may place the patient at unacceptable risk to participate in the study.

* pregnancy, nursing mothers, and women of childbearing potential who are unable to use adequate contraception. * known hypersensitivity or other clear contraindication to the use of colchicine. * history of end-stage renal disease (egfr \<30 ml / min / 1.73 m2). * medical history of cirrhosis (child-pugh c), liver failure, chronic active hepatitis, or severe liver disease defined by alanine aminotransferase (alt) or aspartate aminotransferase (ast)\> 5 times the upper limit of normal. * history of pre-existing neuromuscular disease. * previous severe hematologic disease or bleeding disorders. * inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea, or malabsorptive syndrome. * colchicine treatment for other indications. * treatment with immunosuppressive/immunomodulatory agents, including glucocorticoids, antivirals, antimalarials, and il 6 antagonists for 30 days prior to enrollment. * use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion. * any medical condition or disease that, in the opinion of the investigator, may place the patient at unacceptable risk to participate in the study.

- pregnancy, nursing mothers, and women of childbearing potential who are unable to use adequate contraception. - known hypersensitivity or other clear contraindication to the use of colchicine. - history of end-stage renal disease (egfr <30 ml / min / 1.73 m2). - medical history of cirrhosis (child-pugh c), liver failure, chronic active hepatitis, or severe liver disease defined by alanine aminotransferase (alt) or aspartate aminotransferase (ast)> 5 times the upper limit of normal. - history of pre-existing neuromuscular disease. - previous severe hematologic disease or bleeding disorders. - inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea, or malabsorptive syndrome. - colchicine treatment for other indications. - treatment with immunosuppressive/immunomodulatory agents, including glucocorticoids, antivirals, antimalarials, and il 6 antagonists for 30 days prior to enrollment. - use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion. - any medical condition or disease that, in the opinion of the investigator, may place the patient at unacceptable risk to participate in the study.

- pregnancy, nursing mothers, and women of childbearing potential who are unable to use adequate contraception. - known hypersensitivity or other clear contraindication to the use of colchicine. - history of end-stage renal disease (egfr <30 ml / min / 1.73 m2). - medical history of cirrhosis (child-pugh c), liver failure, chronic active hepatitis, or severe liver disease defined by alanine aminotransferase (alt) or aspartate aminotransferase (ast)> 5 times the upper limit of normal. - history of pre-existing neuromuscular disease. - previous severe hematologic disease or bleeding disorders. - inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea, or malabsorptive syndrome. - colchicine treatment for other indications. - treatment with immunosuppressive/immunomodulatory agents, including glucocorticoids, antivirals, antimalarials, and il 6 antagonists for 30 days prior to enrollment. - use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion. - any medical condition or disease that, in the opinion of the investigator, may place the patient at unacceptable risk to participate in the study.